Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Miscellaneous

This Phase 1 / 2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Miscellaneous
I/II
Mohan, Sanjay
NCT04455841
VICCHEMP2051

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: